Pyroglutamation, a post-translational modification induced by glutaminyl cyclase, can modulate the binding affinity of therapeutic antibodies, as demonstrated for targets CD47 and TRP1, which has potential to influence therapy design and outcome.
- Anneloes van der Plas - van Duijn
- Levi M. T. Winkelman
- Ferenc. A. Scheeren
